four
six
coronavirus
cov
made
transit
mammalianavian
host
human
endem
human
popul
typic
associ
mild
selflimit
respiratori
ill
howev
remain
two
human
cov
caus
sever
respiratori
syndrom
associ
consider
mortal
sever
acut
respiratori
syndrom
sar
cov
caus
diseas
outbreak
claim
nearli
live
second
consecut
decad
centuri
new
human
cov
emerg
middl
east
respiratori
syndrom
mer
cov
first
isol
man
saudi
arabia
june
three
year
later
respons
infect
individu
countri
relat
death
case
merscov
report
date
three
quarter
occur
within
sourc
countri
saudi
arabia
tabl
asid
moder
outbreak
unit
arab
emir
uae
travelassoci
spread
countri
middl
east
well
exampl
europ
north
america
africa
asia
typic
result
minim
local
outbreak
clear
except
situat
republ
korea
case
report
infect
index
case
follow
recent
travel
saudi
arabia
qatar
uae
bahrain
intern
health
regul
emerg
committe
highlight
five
main
factor
contribut
spread
merscov
republ
korea
briefli
lack
awar
among
healthcar
worker
gener
public
suboptim
infect
prevent
control
measur
hospit
crowd
emerg
room
multib
hospit
room
practic
patient
seek
care
multipl
hospit
multipl
visitor
stay
infect
patient
hospit
room
overal
clinic
experi
merscov
indic
spread
within
human
popul
requir
close
contact
major
case
result
humantohuman
transmiss
healthcar
set
good
potenti
outbreak
contain
given
suitabl
level
awar
hygien
latest
outbreak
korea
howev
testament
cost
neglect
basic
requir
recent
studi
group
demonstr
impress
rapid
virucid
activ
povidon
iodin
pvpi
ebola
viru
ebov
pvpi
also
effect
european
refer
viru
modifi
vaccinia
viru
ankara
mva
determin
suitabl
surrog
test
agent
facilit
safe
test
virucid
activ
antisept
product
hazard
pathogen
includ
envelop
virus
ebov
pvpi
broadspectrum
antimicrobi
use
global
medic
middl
disinfect
skin
hand
mucos
surfac
well
wound
treatment
eye
applic
may
hypothes
pvpi
would
also
demonstr
effect
disinfect
properti
merscov
studi
report
evalu
skin
cleanser
surgic
scrub
garglemouthwash
formul
pvpi
virucid
activ
refer
viru
mva
merscov
three
pvpi
antisept
product
test
studi
pvpi
skin
cleanser
pvpi
surgic
scrub
pvpi
garglemouthwash
brand
name
betadin
manufactur
mundipharma
limburg
germani
articl
contain
new
studi
human
anim
subject
perform
author
methodolog
propag
mva
describ
briefli
babi
hamster
kidney
cell
bhk
cell
cell
bank
friedrichloefflerinstitut
germani
infect
mva
institut
anim
hygien
veterinari
public
health
univers
leipzig
germani
cultur
humid
atmospher
viru
cultiv
confluent
monolay
maximum
age
day
cultiv
merscov
base
overal
method
mva
merscov
erasmu
medic
center
rotterdam
netherland
use
test
viru
vero
cell
american
type
cultur
collect
atcc
use
viru
cultiv
suspens
test
test
carri
accord
test
assay
compris
viru
suspens
interf
substanc
clean
gl
bovin
serum
albumin
bsa
dirti
gl
bsa
mll
erythrocyt
pvpi
product
undilut
dilut
viru
control
mixtur
also
assess
use
doubledistil
water
place
test
product
specifi
contact
time
virucid
activ
immedi
suppress
dilut
nine
volum
icecold
medium
minim
essenti
medium
fetal
calf
serum
serial
dilut
tenfold
infect
determin
mean
end
point
dilut
titrat
microtit
plate
aliquot
dilut
ad
six
sampl
cell
cultur
examin
microscop
cytopath
effect
cpe
day
inocul
viru
titer
determin
use
method
express
tissu
cultur
infecti
dose
virucid
activ
determin
differ
logarithm
titer
viru
control
minu
logarithm
titer
test
viru
differ
present
reduct
factor
rf
includ
confid
interv
ci
reduct
viru
titer
correspond
inactiv
regard
evid
suffici
virucid
activ
calcul
perform
accord
accord
inactiv
test
conduct
one
part
merscov
suspens
mix
either
gl
bsa
clean
condit
gl
bsa
mll
erythrocyt
dirti
condit
interf
substanc
mixtur
ad
part
undilut
test
product
contact
time
test
mixtur
ad
ml
icecold
medium
aliquot
dilut
sampl
ad
well
contain
indic
cell
cell
cultiv
day
inspect
microscop
day
virusinduc
cpe
cell
morpholog
calcul
viral
titer
case
viru
low
viral
count
detail
test
concentr
contact
period
chosen
observ
point
test
prepar
produc
effici
viru
inactiv
demonstr
virucid
efficaci
disinfect
antisept
product
requir
produc
reduct
viru
titer
least
reduct
factor
produc
test
product
clean
dirti
condit
time
point
shown
tabl
pvpi
formul
reduct
viral
titer
demonstr
clean
dirti
condit
undilut
dilut
except
garglemouthwash
dirti
condit
requir
exposur
dilut
clean
dirti
condit
virucid
activ
pvpi
product
vari
concentr
avail
iodin
follow
scrub
gl
gl
gl
cleanser
gl
gl
gl
garglemouthwash
gl
gl
gl
titer
merscov
present
control
sampl
rang
clean
dirti
condit
merscov
viral
titer
reduc
tabl
correspond
reduct
merscov
viral
titer
product
test
case
ebola
merscov
envelop
viru
high
biosafeti
level
vaccin
specif
antivir
treatment
infect
remain
case
may
typic
caus
sever
respiratori
diseas
first
year
follow
first
report
case
twothird
patient
suffer
sever
diseas
third
report
case
date
fatal
contain
spread
proven
achiev
case
thu
far
sustain
humantohuman
transmiss
occur
anywher
world
howev
lack
awar
among
health
care
worker
gener
public
coupl
inadequ
prevent
control
procedur
result
outbreak
base
nosocomi
infect
recent
observ
republ
korea
base
current
situat
world
health
organ
issu
number
recommend
mani
reflect
lack
understand
human
becom
infect
anim
environment
sourc
particular
emphasi
precaut
relat
exposur
camel
focu
ensur
health
care
facil
adopt
appropri
measur
decreas
risk
transmiss
viru
infect
patient
patient
health
care
worker
visitor
practic
measur
applic
issu
implement
effect
hand
hygien
practic
standard
hand
hygien
includ
either
wash
hand
soap
water
use
alcoholbas
hand
rub
random
control
trial
data
avail
support
effect
pvpi
alcohol
hand
rub
plain
soap
hand
wash
hand
decontamin
base
posthygien
colonyform
unit
count
context
virucid
activ
pvpi
demonstr
superior
ethanolbas
sanit
inactiv
murin
noroviru
modifi
finger
pad
test
evalu
effect
nine
differ
hand
sanit
felin
caliciviru
surrog
noroviru
antisept
contain
pvpi
achiev
greater
viral
reduct
rate
alcoholbas
sanit
nonalcohol
sanit
antimicrobi
soap
pvpi
demonstr
virucid
activ
rang
envelop
nonenvelop
virus
perhap
relev
context
merscov
evid
effect
inactiv
sarscov
detect
level
within
min
exposur
effect
hand
hygien
crucial
minim
viral
transmiss
contamin
hand
infect
individu
either
direct
persontoperson
contact
indirectli
via
contamin
surfac
howev
respiratori
virus
also
subject
airborn
particl
size
droplet
transmiss
infect
materi
releas
infect
individu
breath
cough
sneez
gargl
repres
effect
person
hygien
measur
airbornedroplet
transmiss
reduc
microb
count
pharynx
togeth
hand
wash
mask
use
propos
gargl
one
three
major
person
hygien
protect
measur
common
airborn
droplettransmit
infect
specialist
advis
criteria
select
mouthwash
includ
effect
antisept
agent
kill
pathogen
given
strong
vitro
virucid
activ
pvpi
demonstr
studi
garglingflush
pvpi
may
effect
measur
disrupt
transmiss
respiratori
virus
especi
via
airbornedroplet
transmiss
uptak
via
mouth
touch
mouth
food
contamin
hand
data
report
indic
rapid
virucid
activ
three
formul
pvpi
mva
merscov
exposur
time
assess
studi
virucid
kinet
pvpi
mva
time
minimum
contact
time
hygien
hand
rub
hand
wash
defin
yet
prove
suffici
three
formul
effect
mva
merscov
merscov
harm
envelop
viru
requir
high
biosafeti
level
investig
recommend
disinfect
test
use
highli
contagi
harm
virus
thu
model
virus
use
centc
committe
establish
standard
european
test
method
requir
antimicrobi
efficaci
chemic
disinfect
antisept
recent
implement
envelop
mva
model
viru
claim
virucid
activ
envelop
virus
hygien
hand
rub
hand
wash
mva
chosen
basi
low
biosafeti
level
known
environment
stabil
practic
laboratori
use
basi
practic
safeti
concern
studi
conduct
primarili
use
mva
confirm
merscov
usual
low
titer
merscov
harvest
cell
cultur
result
rang
demonstr
least
reduct
viru
titer
necessari
test
mixtur
contain
low
viru
titer
undergo
detoxif
molecular
siev
use
sensit
assay
lvp
lvp
high
volum
lowest
appar
noncytotox
dilut
inactiv
assay
test
mixtur
ad
detector
cell
line
cultur
monitor
virusspecif
effect
use
method
larger
reduct
viru
titer
shown
even
lower
viral
load
contact
time
short
test
minim
impact
effect
lvp
offer
suffici
sensit
reduct
viru
titer
detect
even
use
test
product
highli
cytotox
cell
cultur
consid
result
vitro
analysi
suitabl
basi
predict
virucid
efficaci
pvpi
provid
direct
inform
effect
product
practic
howev
taken
togeth
emphasi
place
ensur
suitabl
level
hand
hygien
recommend
gargl
antisept
mouthwash
control
common
airborn
droplettransmit
infect
fact
pvpi
product
alreadi
use
avail
within
affect
region
world
data
provid
strong
rational
use
pvpi
product
prevent
infect
merscov
improv
awar
need
health
care
set
ensur
effect
contain
spread
often
fatal
viru
outbreak
merscov
republ
korea
testament
ongo
risk
healthcareassoci
transmiss
reinforc
need
time
diagnosi
implement
prevent
control
measur
three
pvpi
product
test
studi
demonstr
virucid
activ
mva
merscov
room
temperatur
within
exposur
observ
clean
dirti
condit
data
consist
studi
demonstr
excel
virucid
activ
pvpi
envelop
virus
data
report
indic
pvpibas
hand
wash
product
potenti
contamin
skin
togeth
pvpi
garglemouthwash
reduct
viral
load
oral
caviti
oropharynx
may
help
support
hygien
measur
outbreak
respiratori
virus
